title: Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study.
abstract: Phosphodiesterase type 5 (PDE5) inhibitors have recently been shown to have cognitive-enhancing effects in animal models and in our previous pilot study. To investigate the efficacy of daily low-dose treatment with a PDE5 inhibitor on cognitive function, depression and somatization in patients with erectile dysfunction (ED), 8-week, double-blind, placebo-controlled study enrolled 60 male patients with ED for ≥ 3 months without cognitive impairment. Forty-nine patients completed the study. Patients were randomized to receive either daily low-dose udenafil 50 mg or placebo for 2 months. The International Index of Erectile Function-5 (IIEF-5), the Korean version of the Mini-Mental State Examination (K-MMSE) for general cognitive function and the Seoul Neuropsychological Screening Battery for comprehensive neuropsychological examination, the Physical Health Questionnaire-9 (PHQ-9) for depression and the Physical Health Questionnaire-15 (PHQ-15) for somatization were administered at baseline and at 2 months. The change in the mean IIEF-5 was significantly higher in the udenafil group than the placebo group (6.08 ± 4.72 vs 2.20 ± 3.50, P=0.008). The changes in the PHQ-9 and PHQ-15 were -2.04 ± 3.14 and -2.17 ± 2.87 in the udenafil group, and 1.20 ± 1.63 and 0.56 ± 2.48 in the placebo group (both, P<0.001). The changes in the K-MMSE and Digit Span Forward were 1.25 ± 1.26 and 0.92 ± 1.02 in the udenafil group, and -0.52 ± 1.19 and -0.24 ± 1.13 in the placebo group (both, P<0.001). However, there were no differences in the other neuropsychological tests. Daily dosing with a PDE5 inhibitor seems to improve cognitive function, depression and somatization, as well as erectile function, in patients with ED.
authors.affiliation: Department of Neurology, Bucheon St Mary's Hospital, Catholic University of Korea, Bucheonl, Korea.
authors.forename: Y S
authors.initials: YS
authors.lastname: Shim
authors.affiliation: Department of Psychiatry, Bucheon St Mary's Hospital, Catholic University of Korea, Bucheonl, Korea.
authors.forename: C-U
authors.initials: CU
authors.lastname: Pae
authors.affiliation: Department of Urology, Bucheon St Mary's Hospital, Catholic University of Korea, Bucheonl, Korea.
authors.forename: K J
authors.initials: KJ
authors.lastname: Cho
authors.affiliation: Department of Urology, Seoul St Mary's Hospital, Catholic University of Korea, Seoul, Korea.
authors.forename: S W
authors.initials: SW
authors.lastname: Kim
authors.affiliation: Department of Urology, Bucheon St Mary's Hospital, Catholic University of Korea, Bucheonl, Korea.
authors.forename: J C
authors.initials: JC
authors.lastname: Kim
authors.affiliation: Department of Urology, Bucheon St Mary's Hospital, Catholic University of Korea, Bucheonl, Korea.
authors.forename: J S
authors.initials: JS
authors.lastname: Koh
mesh_terms: D000368:Aged; D003071:Cognition / Q000187:drug effects*; D003863:Depression / Q000150:complications / Q000188:drug therapy*; D004311:Double-Blind Method; D007172:Erectile Dysfunction / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D058986:Phosphodiesterase 5 Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*; D000096926:Benzenesulfonamides
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; C419664:udenafil; D000096926:Benzenesulfonamides